布地奈德聯(lián)合螺內(nèi)酯對(duì)支氣管肺發(fā)育不良早產(chǎn)兒血液中IL-1β、TNF-α變化的影響

葉旭強(qiáng)　戴怡蘅　劉衛(wèi)東?曾立軍　麥麗珊　張李霞

【摘要】 目的：探討布地奈德聯(lián)合螺內(nèi)酯對(duì)支氣管肺發(fā)育不良（BPD）早產(chǎn)兒血液中IL-1β、TNF-α變化的影響。方法：選取2012年11月-2017年11月在本院出生的早產(chǎn)兒92例，患兒均有BPD癥狀。按照隨機(jī)數(shù)字表法將其分為對(duì)照組與研究組，各46例。對(duì)照組給予螺內(nèi)酯治療，研究組應(yīng)用布地奈德聯(lián)合螺內(nèi)酯治療。對(duì)比兩組炎性因子水平（IL-1β、TNF-α、IL-8）、臨床指標(biāo)、體重、血?dú)夥治鲋笜?biāo)、并發(fā)癥。結(jié)果：治療后，研究組IL-1β、TNF-α、IL-8水平均低于對(duì)照組（P<0.05）;治療后，研究組心率、呼吸頻率、經(jīng)皮血氧飽和度、體重、血?dú)夥治鲋笜?biāo)均優(yōu)于對(duì)照組（P<0.05）;研究組并發(fā)癥發(fā)生率為8.7%，低于對(duì)照組的32.6%，差異有統(tǒng)計(jì)學(xué)意義（字2=8.026，P<0.05）。結(jié)論：應(yīng)用布地奈德聯(lián)合螺內(nèi)酯治療早產(chǎn)兒BPD，可以顯著改善患兒血液中IL-1β、TNF-α、IL-8等炎性因子水平，調(diào)節(jié)血?dú)庵笜?biāo)，安全有效，值得推廣。

【關(guān)鍵詞】 布地奈德; 螺內(nèi)酯; 支氣管肺發(fā)育不良; 早產(chǎn)兒; IL-1β; TNF-α

Effect of Budesonide Combined with Spironolactone on Changes of IL-1β and TNF-α in Blood of Premature Infants with Bronchopulmonary Dysplasia/YE Xuqiang，DAI Yiheng，LIU Weidong，et al.//Medical Innovation of China，2019，16（19）：0-057

【Abstract】 Objective：To investigate the effect of Budesonide combined with Spironolactone on the changes of IL-1β and TNF-α in blood of premature infants with bronchopulmonary dysplasia（BPD）.Method：92 cases of premature infants born in our hospital from November 2012 to November 2017 were selected，all of them had BPD symptoms.According to the random number table method，they were divided into control group and study group，46 cases in each group.The control group was treated with Spironolactone，while study group was treated with Budesonide combined with Spironolactone.The levels of inflammatory factors（IL-1β，TNF-α，IL-8），clinical indicators，body weight，blood gas analysis indicators and complications were compared between two groups.Result：After treatment，the levels of IL-1β，TNF-α，IL-8 in study group were lower than those of control group（P<0.05）.After treatment，the indexes of heart rate，respiratory rate，percutaneous oxygen saturation，body weight and blood gas analysis in study group were better than those of control group（P<0.05）.The incidence of complications was 8.7% in study group，which was lower than 32.6% of control group（字2=8.026，P<0.05）.Conclusion：The application of Budesonide combined with Spironolactone in treatment of BPD in premature infants can significantly improve the levels of IL-1β，TNF-α，IL-8 and other inflammatory factors in the blood of the infants，regulate blood gas indicators，which is safe and effective，and is worthy of promotion.

【Key words】 Budesonide; Spironolactone; Bronchopulmonary dysplasia; Premature infants; IL-1β; TNF-αFirst-authors address：Foshan Maternal and Child Health Hospital，F(xiàn)oshan 528000，China

doi：10.3969/j.issn.1674-4985.2019.19.014

支氣管肺發(fā)育不良（BPD）常見(jiàn)于早產(chǎn)兒，臨床特征表現(xiàn)為對(duì)氧氣的長(zhǎng)時(shí)間依賴(lài)，屬慢性呼吸系統(tǒng)的常見(jiàn)病，嚴(yán)重呼吸窘迫綜合征為其原發(fā)疾病，影響患兒機(jī)體發(fā)育[1]。隨著現(xiàn)代醫(yī)療技術(shù)水的提高，早產(chǎn)兒的存活率也有所提升，因此隨之出現(xiàn)的BPD、神經(jīng)系統(tǒng)發(fā)育異常等早產(chǎn)兒病變也出現(xiàn)了較高的發(fā)生率。由于早產(chǎn)，患兒機(jī)體肺未完全發(fā)育，肺泡數(shù)量少，伴隨機(jī)體不斷發(fā)育，肺泡數(shù)量也持續(xù)增多，由于感染、機(jī)械通氣、炎性反應(yīng)等諸多不利因素的作用，患兒極易出現(xiàn)肺泡停滯發(fā)育的狀況，影響患兒身體發(fā)育[2]。當(dāng)前階段，針對(duì)早產(chǎn)兒BPD的防治，尚無(wú)系統(tǒng)規(guī)范化治療方案，主要措施有氧療、支氣管擴(kuò)張劑、抗生素、肺泡表面活性劑、一氧化氮、糖皮質(zhì)激素、維生素A、利尿劑等治療[3]，其中糖皮質(zhì)激素的預(yù)防及治療作用被證實(shí)是有效的，布地奈德為吸入性糖皮質(zhì)激素，療效類(lèi)似于其他類(lèi)糖皮質(zhì)激素，具有防治BPD的功效[4]。本研究對(duì)BPD早產(chǎn)兒進(jìn)行布地奈德聯(lián)合螺內(nèi)酯治療，將布地奈德聯(lián)合螺內(nèi)酯治療對(duì)血液中IL-1β、TNF-α變化的影響以及相關(guān)不良反應(yīng)發(fā)生狀況進(jìn)行探討，現(xiàn)報(bào)道如下。